NF2 BioSolutions signed a contract in July 2019 to partially fund an NF2 Gene Therapy Pilot Pre-Clinical Study at the Abigail Wexner Research Institute at Nationwide Children’s Hospital (NCH) by Dr. Kathrin Meyer, who is serving as the Principal Investigator.
NF2 BioSolutions is sponsoring two researchers to work along with Dr. Meyer, and they will be 100% dedicated to NF2 research in order to facilitate this project in the most timely manner possible. This lab is considered to be one of the top gene therapy labs in the world. Finally, NF2 patients and families can be assured that the best gene therapy researchers are working on curing NF2, but NF2 Biosolutions needs your support to help fund these projects.
Dr. Meyer will be the principal investigator for this NF2 project. Dr Meyer focuses on studying disease mechanisms in neurodegenerative diseases and finding new innovative therapeutic strategies for them. A main emphasis is understanding the impact of different mutations on disease course and severity. Moreover, Dr. Meyer’s lab has a strong translational focus in her projects with the goal to move additional programs towards clinical trials. These projects include the optimization of delivery strategies and evaluation of efficacy and targeting of various areas of the nervous system with gene therapy.
Watch the TV report on how NF2 BioSolutions supports Dr Meyer’s lab and the NF2 journey of Victoria Cooke, the daughter of Steve Cooke, board member of NF2 BioSolutions.
Investigators at the Center for Gene Therapy in The Research Institute at Nationwide Children’s Hospital are currently conducting numerous clinical research studies on other diseases like Batten, Charcot-Marie-Tooth Neuropathy Type 1, Duchenne Muscular Dystrophy, Mucopolysaccharidosis (MPS). See the list here.
The recently FDA approved gene therapy for treatment of the fatal genetic disorder SMA was developed at Nationwide Children’s Hospital. This approval was groundbreaking and is the first and only systemically administered gene therapy approved by the FDA in the US.
Read more about how NCH became ground zero for gene therapy : https://xconomy.com/national/2019/04/15/how-an-ohio-kids-hospital-quietly-became-ground-zero-for-gene-therapy/
To support the funding of this project, please donate to NF2 BioSolutions.